title: Maternal Neutralization-Resistant Virus Variants Do Not Predict Infant HIV Infection Risk.
abstract: Mother-to-child transmission (MTCT) of HIV provides a setting for studying immune correlates of protection. Neutralizing antibodies (NAbs) are suggested to contribute to a viral bottleneck during MTCT, but their role in blocking transmission is unclear, as studies comparing the NAb sensitivities of maternal viruses have yielded disparate results. We sought to determine whether transmitting mothers differ from nontransmitting mothers in the ability to neutralize individual autologous virus variants present at transmission. Ten transmitting and 10 nontransmitting HIV-infected mothers at high risk of MTCT were included in this study. Full-length HIV envelope genes (n = 100) were cloned from peripheral blood mononuclear cells obtained near transmission from transmitting mothers and at similar time points from nontransmitting mothers. Envelope clones were tested as pseudoviruses against contemporaneous, autologous maternal plasma in neutralization assays. The association between transmission and the log2 50% inhibitory concentration (IC50) for multiple virus variants per mother was estimated by using logistic regression with clustered standard errors. t tests were used to compare proportions of neutralization-resistant viruses. Overall, transmitting mothers had a median IC50 of 317 (interquartile range [IQR], 202 to 521), and nontransmitting mothers had a median IC50 of 243 (IQR, 95 to 594). Transmission risk was not significantly associated with autologous NAb activity (odds ratio, 1.25; P = 0.3). Compared to nontransmitting mothers, transmitting mothers had similar numbers of or fewer neutralization-resistant virus variants, depending on the IC50 neutralization resistance cutoff. In conclusion, HIV-infected mothers harbor mostly neutralization-sensitive viruses, although resistant variants were detected in both transmitting and nontransmitting mothers. These results suggest that MTCT during the breastfeeding period is not driven solely by the presence of maternal neutralization escape variants.
  
  
  OBJECTIVE
  There are limited data demonstrating whether NAbs can prevent HIV transmission and infection in humans, and for this reason, NAbs have been studied in MTCT, where maternal antibodies are present at the time of transmission. Results of these studies have varied, perhaps because of differences in methods. Importantly, studies often used cultured viruses and samples from time points outside the window of transmission, which could confound findings. Here, we considered the role of maternal NAbs against individual maternal virus variants near the time of transmission. We found no evidence that NAbs are associated with protection from infection. In fact, depending on the cutoff used to define neutralization resistance, we found evidence that nontransmitting mothers have more neutralization-resistant virus variants. These results suggest that lack of virus transmission in the early breastfeeding period is not simply due to an absence of maternal neutralization escape variants and likely includes multiple factors.
authors.affiliation: Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Medical Scientist Training Program, University of Washington School of Medicine, Seattle, Washington, USA Department of Global Health, University of Washington, Seattle, Washington, USA.
authors.forename: Caitlin
authors.initials: C
authors.lastname: Milligan
authors.affiliation: Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Department of Global Health, University of Washington, Seattle, Washington, USA.
authors.forename: Maxwel M
authors.initials: MM
authors.lastname: Omenda
authors.affiliation: Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Department of Global Health, University of Washington, Seattle, Washington, USA.
authors.forename: Vrasha
authors.initials: V
authors.lastname: Chohan
authors.affiliation: Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors.forename: Katherine
authors.initials: K
authors.lastname: Odem-Davis
authors.affiliation: Department of Global Health, University of Washington, Seattle, Washington, USA Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Department of Biostatistics, University of Washington, Seattle, Washington, USA.
authors.forename: Barbra A
authors.initials: BA
authors.lastname: Richardson
authors.affiliation: Department of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
authors.forename: Ruth
authors.initials: R
authors.lastname: Nduati
authors.affiliation: Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Medical Scientist Training Program, University of Washington School of Medicine, Seattle, Washington, USA joverbau@fredhutch.org.
authors.forename: Julie
authors.initials: J
authors.lastname: Overbaugh
mesh_terms: D057134:Antibodies, Neutralizing / Q000276:immunology*; D005260:Female; D006678:HIV / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000635:transmission*; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical; D020128:Inhibitory Concentration 50; D009500:Neutralization Tests; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology*; D018570:Risk Assessment
chemical_list: D057134:Antibodies, Neutralizing; D015483:HIV Antibodies
references.citation: PLoS Pathog. 2014 Aug;10(8):e1004283
references.pmid: 25144453
references.citation: J Exp Med. 2014 Sep 22;211(10):2061-74
references.pmid: 25155019
references.citation: J Clin Invest. 2015 Jul 1;125(7):2702-6
references.pmid: 26053661
references.citation: J Med Primatol. 2015 Oct;44(5):296-300
references.pmid: 26101933
references.citation: JAMA. 2000 Mar 1;283(9):1167-74
references.pmid: 10703779
references.citation: J Infect Dis. 2001 Jan 15;183(2):206-212
references.pmid: 11120927
references.citation: Scand J Immunol. 2001 Mar;53(3):302-9
references.pmid: 11251889
references.citation: J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):435-40
references.pmid: 11981358
references.citation: AIDS Res Hum Retroviruses. 2002 May 20;18(8):567-76
references.pmid: 12036486
references.citation: Virology. 2002 Aug 15;300(1):109-17
references.pmid: 12202211
references.citation: Scand J Immunol. 2002 Dec;56(6):642-4
references.pmid: 12472677
references.citation: J Infect Dis. 1999 Aug;180(2):344-50
references.pmid: 10395848
references.citation: J Acquir Immune Defic Syndr. 1999 Aug 1;21(4):259-65
references.pmid: 10428102
references.citation: J Virol. 2006 Jan;80(2):835-44
references.pmid: 16378985
references.citation: J Infect Dis. 2006 Jun 1;193(11):1504-11
references.pmid: 16652277
references.citation: J Virol. 2006 Jul;80(13):6525-33
references.pmid: 16775339
references.citation: Curr HIV Res. 2007 Mar;5(2):189-97
references.pmid: 17346133
references.citation: J Virol. 2007 Oct;81(19):10232-41
references.pmid: 17652386
references.citation: Rev Med Virol. 2007 Nov-Dec;17(6):381-403
references.pmid: 17542053
references.citation: J Med Virol. 2009 May;81(5):768-78
references.pmid: 19319941
references.citation: Virology. 2009 May 10;387(2):388-94
references.pmid: 19303619
references.citation: Nat Med. 2009 Aug;15(8):951-4
references.pmid: 19525965
references.citation: Virology. 2010 May 10;400(2):164-74
references.pmid: 20096914
references.citation: PLoS One. 2010;5(4):e10213
references.pmid: 20422033
references.citation: J Virol. 2011 Mar;85(6):2751-63
references.pmid: 21191008
references.citation: J Infect Dis. 2004 Nov 15;190(10):1880-8
references.pmid: 15499546
references.citation: J Clin Invest. 1992 Jun;89(6):1923-30
references.pmid: 1601999
references.citation: J Infect Dis. 1993 Jul;168(1):207-10
references.pmid: 8515110
references.citation: Clin Exp Immunol. 1993 Jul;93(1):56-64
references.pmid: 8324904
references.citation: AIDS. 1993 Nov;7 Suppl 2:S45-8
references.pmid: 8161445
references.citation: JAMA. 1994 Aug 10;272(6):467-74
references.pmid: 8040983
references.citation: J Pediatr. 1995 Jun;126(6):865-71
references.pmid: 7776085
references.citation: Clin Exp Immunol. 1995 Dec;102(3):476-80
references.pmid: 8536360
references.citation: Pediatr Infect Dis J. 1996 Apr;15(4):315-20
references.pmid: 8866800
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jan 1;17(1):92-4
references.pmid: 9436766
references.citation: AIDS Res Hum Retroviruses. 1998 Apr 10;14(6):475-81
references.pmid: 9566549
references.citation: J Virol. 2011 Aug;85(16):8253-62
references.pmid: 21593171
references.citation: J Virol. 2012 Apr;86(8):4129-38
references.pmid: 22301151
references.citation: J Virol. 2012 Oct;86(19):10540-6
references.pmid: 22811522
references.citation: Nat Rev Microbiol. 2012 Dec;10(12):852-67
references.pmid: 23154262
references.citation: Curr Opin HIV AIDS. 2013 Jul;8(4):255-61
references.pmid: 23615116
references.citation: PLoS One. 2013;8(7):e69274
references.pmid: 23874931
references.citation: J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):163-6
references.pmid: 23774880